首页> 外文期刊>Vaccine >Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector
【24h】

Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector

机译:具有复制能力的基于人腺病毒的3型载体作为活疫苗候选载体和病毒传递载体的构建和表征

获取原文
获取原文并翻译 | 示例
           

摘要

In southern China, as well as in neighboring Asian regions, human adenovirus type 3 (HAdV-3) outbreaks have become very prevalent in recent years. To address this problem regionally and globally, a recombinant virus has been constructed, containinga full-length infectious genomic clone of HAdV-3, to act as a vaccine. This was constructed by using a bacterial homologous recombination mechanism and was based on the cloning, manipulation and maintenance of the full-length adenovirus genome as a stable plasmid in E. coli. The resultant recombinant viral DNA was screened, identified and characterized by duplex PCR, Western blot, indirect immunofluorescence assay and electron microscopy. This putative vaccine strain was shown to be fully infectious inpermissive cells, and no genome mutations were found in the recombinant plasmid. To demonstrate the utility of such a vaccine, a recombinant HAdV-3 plasmid expressing the reporter molecule eGFP was also constructed. This confirmed the recombinant proteinexpression capability. Mice immunized with this recombinant eGFP adenovirus by either intramuscular injection, intragastric or intranasal inoculation routes raised a significant antibody response to eGFP. Our results have provided a solid foundation fordevelopment of a recombinant live vaccine and potential more effective adenovirus vector-based delivery system for immune and gene therapy.
机译:在中国南部以及邻近的亚洲地区,近年来,人类3型腺病毒(HAdV-3)爆发已非常普遍。为了在区域和全球范围内解决该问题,已经构建了重组病毒,其包含HAdV-3的全长感染性基因组克隆,以用作疫苗。这是通过使用细菌同源重组机制构建的,并且基于全长腺病毒基因组的克隆,操纵和维持,该全长腺病毒基因组是大肠杆菌中的稳定质粒。通过双重PCR,蛋白质印迹,间接免疫荧光测定和电子显微镜对所得的重组病毒DNA进行筛选,鉴定和表征。该推定的疫苗株显示为完全感染性的低通细胞,并且在重组质粒中未发现基因组突变。为了证明这种疫苗的效用,还构建了表达报告分子eGFP的重组HAdV-3质粒。这证实了重组蛋白表达能力。通过肌内注射,胃内或鼻内接种途径用该重组eGFP腺病毒免疫的小鼠引起对eGFP的显着抗体应答。我们的结果为开发重组活疫苗和潜在的更有效的基于腺病毒载体的免疫和基因治疗递送系统奠定了坚实的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号